RU2743409C2 - Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента - Google Patents

Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента Download PDF

Info

Publication number
RU2743409C2
RU2743409C2 RU2018125514A RU2018125514A RU2743409C2 RU 2743409 C2 RU2743409 C2 RU 2743409C2 RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2743409 C2 RU2743409 C2 RU 2743409C2
Authority
RU
Russia
Prior art keywords
masp
complement
activation
seq
ahus
Prior art date
Application number
RU2018125514A
Other languages
English (en)
Russian (ru)
Other versions
RU2018125514A (ru
RU2018125514A3 (https=
Inventor
Грегори А. ДЕМОПУЛОС
Том ДАДЛЕР
Ханс-Вильхельм ШВЕБЛЕ
Original Assignee
Юниверсити Оф Лестер
Омерос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Лестер, Омерос Корпорейшн filed Critical Юниверсити Оф Лестер
Publication of RU2018125514A publication Critical patent/RU2018125514A/ru
Publication of RU2018125514A3 publication Critical patent/RU2018125514A3/ru
Application granted granted Critical
Publication of RU2743409C2 publication Critical patent/RU2743409C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
RU2018125514A 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента RU2743409C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473698P 2011-04-08 2011-04-08
US61/473,698 2011-04-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013149792A Division RU2662563C2 (ru) 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021103424A Division RU2852982C2 (ru) 2011-04-08 2021-02-12 Способы лечения состояний, связанных с masp-2-зависимой активацией комплемента

Publications (3)

Publication Number Publication Date
RU2018125514A RU2018125514A (ru) 2019-03-12
RU2018125514A3 RU2018125514A3 (https=) 2019-10-30
RU2743409C2 true RU2743409C2 (ru) 2021-02-18

Family

ID=46966283

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018125514A RU2743409C2 (ru) 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
RU2013149792A RU2662563C2 (ru) 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013149792A RU2662563C2 (ru) 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента

Country Status (17)

Country Link
US (6) US8951522B2 (https=)
EP (3) EP3964233A1 (https=)
JP (4) JP5937197B2 (https=)
KR (6) KR101870915B1 (https=)
CN (3) CN110075294A (https=)
AU (1) AU2012239889B2 (https=)
BR (1) BR112013025917A2 (https=)
CA (4) CA3076975C (https=)
CL (1) CL2013002874A1 (https=)
DK (2) DK2694108T3 (https=)
ES (2) ES2683307T3 (https=)
IL (3) IL228758B (https=)
MX (3) MX381987B (https=)
NZ (5) NZ731596A (https=)
PL (1) PL3287142T3 (https=)
RU (2) RU2743409C2 (https=)
WO (1) WO2012139081A2 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688182B2 (ja) 1986-09-08 1994-11-09 バブコツク日立株式会社 スタツド着脱装置
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PE20150159A1 (es) * 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
WO2013180834A2 (en) * 2012-04-06 2013-12-05 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
KR102339315B1 (ko) * 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
ES2964340T3 (es) 2013-03-15 2024-04-05 Omeros Corp Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
SMT202000659T1 (it) * 2013-10-17 2021-01-05 Omeros Corp Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2
WO2015070041A1 (en) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108472347B (zh) 2015-11-09 2023-09-05 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2018007392A (es) * 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
WO2017173290A1 (en) 2016-03-31 2017-10-05 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
IL265981B2 (en) * 2016-10-13 2025-05-01 Univ Leicester Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
JP6442703B2 (ja) * 2016-12-26 2018-12-26 日本ビーシージー製造株式会社 細菌細胞壁骨格成分を含有する水中油型エマルション製剤
JPWO2018164186A1 (ja) * 2017-03-09 2020-01-09 協和キリン株式会社 Ｍａｓｐ２の発現を抑制する核酸
AU2018306411B2 (en) * 2017-07-28 2022-03-31 Lemonex Inc. Pharmaceutical composition for preventing or treating liver cancer
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110945130B (zh) 2017-12-01 2024-04-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112867706B (zh) 2018-05-29 2024-11-15 奥默罗斯公司 Masp-2抑制剂和使用方法
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3628735A1 (en) * 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
BR112021008967A2 (pt) * 2018-11-15 2021-08-17 Ionis Pharmaceuticals, Inc. moduladores da expressão de irf5
EP3960858B1 (en) * 2018-12-25 2025-05-07 Beijing Baishihekang Pharmaceutical Technology (BSJpharma) Co., Ltd. Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
JP7530106B2 (ja) * 2019-03-14 2024-08-07 レナセラピューティクス株式会社 Ｉｈｈ発現を調節するための核酸複合体
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
WO2020233680A1 (zh) 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
WO2020233651A1 (zh) * 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7610268B2 (ja) 2019-05-22 2025-01-08 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
EP3978609A4 (en) 2019-05-24 2024-02-07 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗
CN111024947A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 白色念珠菌荧光免疫层析测定试剂盒及其制备方法
WO2021107057A1 (ja) 2019-11-27 2021-06-03 京セラ株式会社 通信制御方法及びユーザ装置
BR112022010881A2 (pt) 2019-12-04 2022-08-23 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021168148A1 (en) * 2020-02-19 2021-08-26 Alnylam Pharmaceuticals, Inc. Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
WO2021231720A1 (en) * 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN113674860B (zh) * 2020-05-15 2024-05-17 北京大学人民医院 一种难治性iTTP风险预测装置、系统及其应用
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
CN114634575B (zh) * 2020-12-16 2025-04-11 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
TW202305010A (zh) * 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
WO2023108028A2 (en) 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
IL317825A (en) * 2022-07-25 2025-02-01 Amgen Inc RNA interference constructs and methods for inhibiting fam13a expression
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
CN119978131B (zh) * 2025-04-15 2025-06-27 北京赛斯维德生物科技有限公司 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032973A2 (en) * 2002-10-09 2004-04-22 Aurelio Maggio Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases
RU2008143559A (ru) * 2006-04-03 2010-05-10 ОМЕРОС КОРПОРЕЙШЕН, Соединенные Штаты Америки (US) Способ лечения заболеваний, связанных с masp-2-зависимой активацией комплемента (варианты)

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
RU2271825C2 (ru) 1999-07-21 2006-03-20 Омерос Корпорейшн Растворы и способы ингибирования боли, воспаления и разрушения хряща
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US20030186419A1 (en) 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
NZ523900A (en) 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
CA2454562A1 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
WO2003081206A2 (en) 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
AU2003249317B2 (en) 2002-07-19 2007-08-02 Institute Of Materials Research And Engineering Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
PT1534313E (pt) 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
EP1570075A2 (en) 2002-12-03 2005-09-07 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1609804B1 (en) * 2003-03-17 2012-06-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2386316B1 (en) * 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
EP1987354B1 (en) 2006-01-27 2010-11-03 Rappaport Family Institute for Research in the Medical Sciences Methods for determining blood coagulation
KR101584468B1 (ko) 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
MX2012005151A (es) * 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP2704743B1 (en) 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
KR102339315B1 (ko) 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
SMT202000659T1 (it) 2013-10-17 2021-01-05 Omeros Corp Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2
CN108472347B (zh) 2015-11-09 2023-09-05 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
WO2017173290A1 (en) * 2016-03-31 2017-10-05 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
JPWO2018070521A1 (ja) * 2016-10-14 2019-08-15 公立大学法人福島県立医科大学 補体の活性化経路を阻害する融合ポリペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032973A2 (en) * 2002-10-09 2004-04-22 Aurelio Maggio Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2008143559A (ru) * 2006-04-03 2010-05-10 ОМЕРОС КОРПОРЕЙШЕН, Соединенные Штаты Америки (US) Способ лечения заболеваний, связанных с masp-2-зависимой активацией комплемента (варианты)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARKER C. Complement and Hematology//The Hematologist, January-February 2011, Volume 8, Issue 1 он лайн, найдено 18.10.2019, найдено в Интернет (https://www.hematology.org/Thehematologist/Mini-Review/6324.aspx). *

Also Published As

Publication number Publication date
CA2977009C (en) 2020-05-05
KR20140009472A (ko) 2014-01-22
US20150239985A1 (en) 2015-08-27
IL228758B (en) 2019-12-31
HK1250342A1 (zh) 2018-12-14
MX381987B (es) 2025-03-13
US20120258095A1 (en) 2012-10-11
US20260062498A1 (en) 2026-03-05
KR20170034941A (ko) 2017-03-29
JP2016185966A (ja) 2016-10-27
CN107638565B (zh) 2021-12-21
DK2694108T3 (en) 2018-08-20
ES2683307T3 (es) 2018-09-26
JP6584476B2 (ja) 2019-10-02
NZ717517A (en) 2017-07-28
NZ731596A (en) 2022-07-01
CL2013002874A1 (es) 2014-03-07
DK3287142T3 (da) 2021-11-01
CN107638565A (zh) 2018-01-30
RU2018125514A (ru) 2019-03-12
KR102217658B1 (ko) 2021-02-22
IL228758A0 (en) 2013-12-31
JP2014512363A (ja) 2014-05-22
CA3076975A1 (en) 2012-10-11
JP5937197B2 (ja) 2016-06-22
JP6239030B2 (ja) 2017-11-29
CN103781492A (zh) 2014-05-07
EP3287142B1 (en) 2021-08-04
RU2013149792A (ru) 2015-05-20
CA3237802A1 (en) 2012-10-11
KR20180072851A (ko) 2018-06-29
KR20190142445A (ko) 2019-12-26
JP2018024698A (ja) 2018-02-15
IL274206A (en) 2020-06-30
WO2012139081A3 (en) 2012-11-29
KR101720562B1 (ko) 2017-03-30
AU2012239889A1 (en) 2013-03-14
KR101870915B1 (ko) 2018-06-25
ES2894342T3 (es) 2022-02-14
EP2694108A4 (en) 2014-10-01
CA2832187A1 (en) 2012-10-11
RU2662563C2 (ru) 2018-07-26
JP6893539B2 (ja) 2021-06-23
AU2012239889B2 (en) 2015-09-03
IL264172A (en) 2019-02-28
MX355648B (es) 2018-04-26
US20170166658A1 (en) 2017-06-15
US8951522B2 (en) 2015-02-10
PL3287142T3 (pl) 2021-12-27
US20220089781A1 (en) 2022-03-24
EP3964233A1 (en) 2022-03-09
CA3076975C (en) 2024-06-18
US20190292272A1 (en) 2019-09-26
NZ617298A (en) 2015-08-28
EP3287142A1 (en) 2018-02-28
JP2019214616A (ja) 2019-12-19
KR20220044616A (ko) 2022-04-08
US10202465B2 (en) 2019-02-12
BR112013025917A2 (pt) 2016-12-20
IL264172B (en) 2022-04-01
CA2832187C (en) 2017-10-10
MX2013011721A (es) 2014-03-05
CA2977009A1 (en) 2012-10-11
RU2018125514A3 (https=) 2019-10-30
NZ746139A (en) 2023-11-24
CN110075294A (zh) 2019-08-02
WO2012139081A2 (en) 2012-10-11
NZ709997A (en) 2016-03-31
EP2694108A2 (en) 2014-02-12
KR20210021101A (ko) 2021-02-24
EP2694108B1 (en) 2018-06-06
MX339002B (es) 2016-05-06

Similar Documents

Publication Publication Date Title
US20260062498A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
US20250059299A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
RU2718850C2 (ru) Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
RU2852982C2 (ru) Способы лечения состояний, связанных с masp-2-зависимой активацией комплемента
RU2830289C2 (ru) Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
HK40069993A (en) Methods for treating conditions associated with masp-2 dependent complement activation
HK1250342B (zh) 用於治疗与masp-2依赖性补体活化相关的状况的方法
HK1194680A (en) Methods for treating conditions associated with masp-2 dependent complement activation
HK1194680B (en) Methods for treating conditions associated with masp-2 dependent complement activation